In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem ...
The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...
The newly combined company will focus on moving Kadimastem's AstroRx, NLS's DOXA platform, and other therapies through ...
Our pipeline includes programs for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and ...
Hosted on MSN13d
Research supports brain cell transplantation as a treatment for some neurological disordersSome diseases are a result of the loss of specific cells, such as the loss of motor neurons in amyotrophic lateral sclerosis (ALS), the loss of dopaminergic ... the recipient is affected by the age of ...
With its ability to improve neuron health, experimental drug NU-9 has already shown promise in reversing amyotrophic lateral ...
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regu ...
In a mouse model of amyotrophic lateral sclerosis, the authors correlated neuronal TMEM106b fibrils with loss of nuclear TDP-43, a hallmark of the disease. Similarly, in a tauopathy mouse model, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback